Table 1 Study population characteristics and medication use
From: The anti-ageing molecule sirt1 mediates beneficial effects of cardiac rehabilitation
Age (y.o.), mean (SD) | 68.6 (6.3) | Medications, n (%) | |
Gender (M/F) | 50/0 | β-blockers | 46 (92) |
BMI (kg/m2), mean (SD) | 28.03 (3.17) | ACE-inhibitors | 29 (58) |
SBP (mmHg), mean (SD) | 122 (6) | ARBs | 9 (18) |
DBP (mmHg), mean (SD) | 80 (9) | Diuretics | 8 (16) |
HR (bpm), mean (SD) | 84 (8) | Nitrates | 6 (12) |
CAD, n (%) | 49 (98) | Ca2+-antagonists | 4 (8) |
ischemic | 47 (94) | α-antagonists | 2 (4) |
hypertrophic | 1 (2) | Aspirin | 46 (92) |
dilatative | 1 (2) | Anticoagulants | 31 (62) |
PTCA, n (%) | 33 (66) | Other cardiac drugs | 3 (6) |
CABG, n (%) | 9 (18) | Antiarrhythmics | 2 (4) |
Valvular substitution, n (%) | 1 (2) | Statins | 49 (98) |
Smoking, n (%) | 35 (70) | Gastro-protective drugs | 44 (88) |
Familiarity, n (%) | 15 (30) | Polyunsaturated fats | 13 (26) |
Hypertension, n (%) | 29 (58) | Oral hypoglycaemics | 9 (18) |
Dyslipidaemia, n (%) | 28 (56) | Insulin | 5 (10) |
Diabetes, n (%) | 13 (26) | ||
COPD, n (%) | 6 (12) | ||
Obesity, n (%) | 4 (8) | ||
Peripheral Artery Disease, n (%) | 2 (4) | ||
Arrhythmias, n (%) | 2 (4) | ||
Distyroidism, n (%) | 1 (2) | ||
Other diseases, n (%) | 1 (2) |